Due to the increasing prevalence of diabetes, hypertension and obesity, the number of patients treated for ESRD is growing at a rate that far exceeds the growth rate of the general population. Hypertension and diabetes alone account for 70% of all newly diagnosed patients with ESRD¹. The aging population and higher life expectancy of patients on dialysis also contributes to the numbers of patients being treated.

Worldwide, 2.5 million patients are treated annually with hemodialysis that requires the creation or revision of a vascular access. And the dialysis population around the world is expected to exceed 3.4 million by 2020. The Ellipsys^® Vascular Access System has the potential to save billions annually in healthcare costs because it does not involve the traditional method requiring surgery.